We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subc... Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts. Show more
Ask ADVFN Intelligence (AI)
Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled Part A 16-week proof-of-concept data anticipated in mid-2025 SAN FRANCISCO and BOSTON...
SAN FRANCISCO and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the...
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.8 | 1.95886385896 | 40.84 | 44.01 | 39.6291 | 429564 | 41.20421147 | CS |
| 4 | -6.45 | -13.4123518403 | 48.09 | 48.09 | 36.48 | 567701 | 39.88743802 | CS |
| 12 | -10.325 | -19.8691426922 | 51.965 | 53.615 | 36.48 | 518763 | 44.39790418 | CS |
| 26 | 0.63 | 1.53621068032 | 41.01 | 63.5 | 36.48 | 447374 | 48.50588644 | CS |
| 52 | 5.84 | 16.312849162 | 35.8 | 72.29 | 33.14 | 512703 | 50.63799751 | CS |
| 156 | 20.14 | 93.6744186047 | 21.5 | 72.29 | 14.19 | 447076 | 43.1828121 | CS |
| 260 | 20.14 | 93.6744186047 | 21.5 | 72.29 | 14.19 | 447076 | 43.1828121 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
